Lv11
44 积分 2024-07-17 加入
In vitro and in vivo ADME of heterobifunctional degraders: a tailored approach to optimize DMPK properties of PROTACs©
4小时前
待确认
Physiological Parameters in Laboratory Animals and Humans
4天前
已完结
RIPTACs for Precision Cancer Therapy: A Novel Modality with the Inspiration of HLD-0915 as the First Candidate in Clinical Trials
21天前
已完结
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2个月前
已完结
Extracellular targeted protein degradation: an emerging modality for drug discovery
3个月前
已完结
Industry Perspective on the Pharmacokinetic and Absorption, Distribution, Metabolism, and Excretion Characterization of Heterobifunctional Protein Degraders
4个月前
已完结
Optimization of Peptide Drug Exposures for Pharmacological Efficacy: DMPK Considerations
5个月前
已完结
Metabolism and Excretion of Therapeutic Peptides: Current Industry Practices, Perspectives, and Recommendations
6个月前
已完结
DRUG-INDUCED LIVER INJURY: MECHANISMS, METHODS FOR PRE-CLINICAL ASSESSMENT, AND A MEDICINAL CHEMIST’S PERSPECTIVE
6个月前
已关闭
Variations in protein binding of drugs in plasma and serum
9个月前
已完结
皖公网安备34019202002308
